Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
32
pubmed:dateCreated
2000-9-14
pubmed:abstractText
Fibroblast growth factors (FGFs) are known to induce formation of new blood vessels, angiogenesis. We show that FGF-induced angiogenesis can be modulated using selectively desulfated heparin. Chinese hamster ovary cells (CHO677) deficient in heparan sulfate biosynthesis were employed to assess the function of heparin/heparan sulfate in FGF receptor-1 (FGFR-1) signal transduction and biological responses. In the presence of FGF-2, FGFR-1 kinase and subsequent mitogen-activated protein kinase Erk2 activities were augmented in a dose-dependent manner, whereas high concentrations of heparin resulted in decreased activity. The length of the heparin oligomer, minimally an 8/10-mer, was critical for the ability to enhance FGFR-1 kinase activity. The N- and 2-O-sulfate groups of heparin were essential for binding to FGF-2, whereas stimulation of FGFR-1 and Erk2 kinases by FGF-2 also required the presence of 6-O-sulfate groups. Sulfation at 2-O- and 6-O-positions was moreover a prerequisite for binding of heparin to a lysine-rich peptide corresponding to amino acids 160-177 in the extracellular domain of FGFR-1. Selectively 6-O-desulfated heparin, which binds to FGF-2 but fails to bind the receptor, decreased FGF-2-induced proliferation of CHO677 cells, presumably by displacing intact heparin. Furthermore, FGF-2-induced angiogenesis in chick embryos was inhibited by 6-O-desulfated heparin. Thus, formation of a ternary complex of FGF-2, heparin, and FGFR-1 appears critical for the activation of FGFR-1 kinase and downstream signal transduction. Preventing complex formation by modified heparin preparations may allow regulation of FGF-2 functions, such as induction of angiogenesis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0021-9258
pubmed:author
pubmed:issnType
Print
pubmed:day
11
pubmed:volume
275
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
24653-60
pubmed:dateRevised
2010-5-26
pubmed:meshHeading
pubmed-meshheading:10816596-Allantois, pubmed-meshheading:10816596-Amino Acid Sequence, pubmed-meshheading:10816596-Animals, pubmed-meshheading:10816596-CHO Cells, pubmed-meshheading:10816596-Cell Division, pubmed-meshheading:10816596-Chick Embryo, pubmed-meshheading:10816596-Chorion, pubmed-meshheading:10816596-Cricetinae, pubmed-meshheading:10816596-Fibroblast Growth Factor 2, pubmed-meshheading:10816596-Heparin, pubmed-meshheading:10816596-Heparitin Sulfate, pubmed-meshheading:10816596-Humans, pubmed-meshheading:10816596-Mitogen-Activated Protein Kinase 1, pubmed-meshheading:10816596-Molecular Sequence Data, pubmed-meshheading:10816596-Neovascularization, Physiologic, pubmed-meshheading:10816596-Peptide Fragments, pubmed-meshheading:10816596-Receptor, Fibroblast Growth Factor, Type 1, pubmed-meshheading:10816596-Receptor Protein-Tyrosine Kinases, pubmed-meshheading:10816596-Receptors, Fibroblast Growth Factor, pubmed-meshheading:10816596-Recombinant Proteins, pubmed-meshheading:10816596-Signal Transduction, pubmed-meshheading:10816596-Structure-Activity Relationship, pubmed-meshheading:10816596-Transfection
pubmed:year
2000
pubmed:articleTitle
Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis.
pubmed:affiliation
Department of Genetics and Pathology, Rudbeck Laboratory, S-751 85 Uppsala, Sweden.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't